The Silver Syndrome Variant of Hereditary Spastic Paraplegia Maps to Chromosome 11q12-q14, with Evidence for Genetic Heterogeneity within This Subtype  by Patel, H. et al.
Am. J. Hum. Genet. 69:209–215, 2001
209
Report
The Silver Syndrome Variant of Hereditary Spastic Paraplegia Maps to
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The hereditary spastic paraplegias (HSPs) are a complex group of neurodegenerative disorders characterized by
lower-limb spasticity and weakness. Silver syndrome (SS) is a particularly disabling dominantly inherited form of
HSP, complicated by amyotrophy of the hand muscles. Having excluded the multiple known HSP loci, we undertook
a genomewide screen for linkage of SS in one large multigenerational family, which revealed evidence for linkage
of the SS locus, which we have designated “SPG17,” to chromosome 11q12-q14. Haplotype construction and
analysis of recombination events permitted the minimal interval defining SPG17 to be refined to ∼13 cM, flanked
by markers D11S1765 and D11S4136. SS in a second family was not linked to SPG17, demonstrating further
genetic heterogeneity in HSP, even within this clinically distinct subtype.
“Hereditary spastic paraplegia” (HSP) is a general term
used to describe the group of disorders characterized by
progressive lower-limb spasticity and weakness. When
spastic paraplegia is the only clinical feature, the disease
is described as “pure” HSP; if accompanied by other
neurological features, such as deafness, dementia, and
mental retardation, the disease is described as “compli-
cated” HSP. The pathological feature common to both
subtypes is axonal degeneration involving the longest
fibers of the corticospinal tracts and of the dorsal col-
umns, which may be associated with a loss of anterior
horn cells (Harding 1993). Although variability in age
at onset, in rate of progression, and in severity are fea-
tures of HSP (Harding 1981; Polo et al. 1993; Du¨rr et
al. 1994; De Jonghe et al. 1996; Nielsen et al. 1997),
the first signs of disease typically are apparent by the 2d
or 3d decade of life.
In addition to marked clinical variation, HSP dem-
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onstrates considerable genetic heterogeneity, with eight
autosomal dominant, four autosomal recessive, and
three X-linked loci mapped to date (Hazan et al. 1993,
1994; Hentati et al. 1994; Jouet et al. 1994; Saugier-
Veber et al. 1994; Fink et al. 1995; Casari et al. 1998;
Hedera et al. 1999; Martinez Murrilo et al. 1999; Reid
et al. 1999, 2000; Seri et al. 1999; Claes et al. 2000;
Fontaine et al. 2000; Vazza et al. 2000).
An especially disabling autosomal dominant form of
complicated HSP, termed “Silver syndrome” (SS [MIM
270685]), is characterized by lower-limb spasticity as-
sociated with marked amyotrophy of and weakness of
the small muscles of the hands and the feet (Silver 1966).
Previously, we have excluded linkage of this form of HSP
to any of the known HSP loci (Patel et al., in press).
Having performed a genomewide screen for linkage, we
now present evidence for linkage of SS to chromosome
11q12-q14 and for marked phenotypic variability in this
form of HSP.
Clinical evaluation of two families was undertaken by
two independent examiners (P.H. and T.T.W.), and the
data are summarized in table 1. Patients in two families
with SS (fig. 1) were classified either as definitely, prob-
ably, or possibly affected by HSP or as unaffected, on
the basis of standard criteria (Fink et al. 1996). The
presence of wasting of the small muscles of the hands
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Table 1
Clinical Features of Affected Members of Families 1 and 2
PATIENT
AGE AT
(years) STATUS OFa
Examination Onset
Sphincter
Involvement
Pes
cavus
Amyotrophy of
Hand Muscles
Pyramidal Signs
Vibration SenseUpper Limb Lower Limb
Family 1:
II.1 75 25 … …    N
II.5 77 40s      N
II.7 81 … …     N
III.1 45 20s …     N
III.3 18 15 …     N
III.5 49 20s      N
III.6 53 8 …     N
III.8 55 28 …     N
III.11 57 … …     …
III.13 61 40 …     Impairment in ankles
III.16 42 … …     N
Family 2:
II.6 64 35 …     N
II.10 52 … …     Impairment in ankles
III.2 23 7      N
NOTE.—Data for affected individuals III.7 and IV.1 in family 1 and for affected individuals II.2 and II.5 in family 2 were not available.
a  p Absent;  p mild;  p moderate;  p severe; N p normal.
Figure 1 Structure of SS pedigrees 1 and 2. Blackened symbols denote affected individuals.
and the feet also indicated affected status, but individuals
were classified as definitely affected only if they pre-
sented with lower-limb hyperreflexia and extensor-plan-
tar responses, which could occur without amyotrophy
of the small muscles of the hands and the feet.
Age at onset in family 1 varied for gait abnormalities
(8–40 years) and for hand involvement (14–60 years).
Lower-limb spasticity and amyotrophy of intrinsic hand
muscles was present in the majority of affected individ-
uals. All individuals’ intrinsic hand muscles were weak,
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Table 2
LOD Scores for Chromosome 11 Markers in Family 1
LOCUS
LOD SCORE AT v p
.00 .01 .10 .20 .30 .40 .50
D11S986 .11 .14 1.01 1.30 1.24 .86 .35
D11S4191 .71 .45 .46 .79 .83 .58 .20
D11S1765 .29 .04 .84 1.13 1.08 .74 .29
D11S4205 3.77 3.72 3.45 3.10 2.34 1.50 .62
D11S1883 3.80 3.75 3.48 3.13 2.37 1.53 .64
D11S4178 3.10 3.05 2.82 2.51 1.86 1.13 .40
D11S1889 3.80 3.74 3.47 3.12 2.36 1.53 .64
D11S913 3.77 3.72 3.45 3.10 2.34 1.50 .62
D11S987 3.88 3.82 3.55 3.20 2.44 1.60 .69
D11S4155 .56 .55 .50 .44 .32 .20 .09
D11S4113 3.88 3.82 3.55 3.20 2.44 1.60 .69
D11S4095 3.54 3.49 3.24 2.92 2.22 1.46 .63
D11S1337 .51 .50 .45 .38 .25 .13 .04
D11S4136 .80 .07 .61 .73 .63 .39 .14
D11S4196 2.38 2.34 2.16 1.93 1.42 .88 .34
D11S1314 1.00 1.84 2.28 2.25 1.84 1.23 .52
D11S4184 1.82 1.79 1.64 1.45 1.04 .62 .23
D11S916 .50 .36 .89 .98 .83 .53 .22
D11S4207 .80 .07 .61 .73 .63 .39 .14
D11S4128 .23 .97 1.45 1.49 1.23 .80 .31
D11S1321 .91 1.75 2.19 2.16 1.76 1.16 .48
D11S4081 .81 .79 .72 .64 .46 .28 .12
with severe amyotrophy most marked in the thenar em-
inence. There was also impairment of vibration sense in
the lower limbs of older individuals.
Assignment of affection status to family members was
essentially straightforward, with the exception of indi-
vidual III.11, whose medical history was complicated by
previous pulmonary sarcoidosis and type II diabetes. In-
dividual III.11 did have clinical features consistent with
a diagnosis of HSP—namely, spastic gait, bilateral claw-
ing of the toes, hypertonia of the leg muscles, brisk knee
jerks, and an extensor–left-plantar response—and it was
considered highly likely that he was affected. However,
although there were signs compatible with an ulnar-
nerve lesion at the left elbow, there were no other signs
of amyotrophy.
Previously, linkage of SS in families 1 and 2 to any
of the known autosomal dominant HSP loci (on chro-
mosomes 2p21-p22, 2q24-q34, 8q24, 10q23.3-q24.1,
12q13, 14q11.2-q24.3, 15q11.1, and 19q13) has been
excluded (Patel et al., in press). To map the position
of the SS variant of HSP, a 10-cM–resolution, ge-
nomewide screen for linkage (ABI PRISM Linkage
Mapping Set Version 2 markers; Perkin Elmer Biosys-
tems) was undertaken in family 1. Since male-to-male
transmission of the disorder has been observed in
these families, linkage analysis was confined to the 22
human autosomes. PCRs were performed in either a
GeneAmp PCR system 9700 (Perkin Elmer Biosys-
tems) or a Techne Genius PCR machine. PCR products
were then pooled and size fractionated on a 4% de-
naturing polyacrylamide gel (BioRad), by an ABI377
sequencer (Perkin Elmer Biosystems), according to
recommended protocols. The data were analyzed by
GeneScan Analysis Software 2.1 and GENOTYPER
(version 2.1) (Perkin Elmer Biosystems), to generate
genotypes for linkage analysis.
To investigate regions of uninformativity, further sat-
uration, with an additional 223 markers, was performed
with unlabeled primers (Genosys), with detection on 8%
denaturing PAGE and silver staining. These PCRs were
performed with 200 ng of genomic DNA, reaction buffer
IV containing 1.5 mM MgCl2 (Advanced Biotechnolo-
gies), 5 mM each dNTP, 50 pmol of each primer, and
0.15 units of Red Hot DNA polymerase (Advanced Bi-
otechnologies), in a final volume of 25 ml. Amplifica-
tions were performed with a “hot-start” cycle of 2#
(96C, 4C above calculated annealing, and 72C—all
for 30 s each), 2# (96C, 2C above calculated an-
nealing, and 72C—all for 30 s each), and 35# (96C,
at annealing, and 72C—all for 30 s each).
Two-point LOD scores were calculated, for each
marker, by MLINK (version 5.1) of the LINKAGE pack-
age (Lathrop et al. 1984, 1985), as implemented in
FASTLINK (version 4.1) (Scha¨ffer et al. 1994). For link-
age computations, the gene frequency of HSP was as-
sumed to be 104, and male and female recombination
rates (v) were assumed to be equal. LOD scores were
calculated with equal allele frequencies assumed for all
markers. The map order and distances between markers
were based on the microsatellite-marker map of the Cen-
ter for Medical Genetics, Marshfield Medical Research
Foundation.
In view of the variable penetrance in HSP, LOD scores
were initially computed by a conservative approach,
with affected family members only. In the absence of
published data on age-specific population risks of spas-
ticity and of amyotrophy, a nominal phenocopy risk of
104 was assumed. LOD scores were also calculated by
assigning family members to liability classes. Although
the penetrance of SS cannot be reliably calculated from
a single family, age-specific risks were estimated by sur-
vival analysis (through symptoms specific to age at onset
or through symptoms common within the family). Under
this model, the disease gene confers a cumulative risk of
24% by the age of 20 years and of 70% by the age of
45 years and a lifetime risk of 85%.
Linkage of SS was initially assessed using affected fam-
ily members only and by assigning individual III.11 to
an “unknown” phenotype. This analysis generated pair-
wise LOD scores of 3.51 and 3.49 for chromosome
11q12-q14 markers D11S987 and D11S4113, respec-
tively. Pairwise LOD scores generated under the as-
sumption that individual III.11 is affected for all chro-
mosome 11q12-q14 markers are shown in table 2. A
second analysis was then performed by assigning family
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Figure 3 Haplotype for pedigree 2, showing microsatellites in
the region that shows linkage of SS in family 1. Blackened symbols
denote affected individuals.
members to liability classes. The LOD scores generated
in this manner were not significantly different from those
determined in the analysis based on an affecteds-only
model.
Haplotype construction revealed that each of the 14
affected family members had inherited an identical region
of chromosome 11q12-q14 (fig. 2). Recombination events
across this region positioned the locus, which we have
designated “SPG17,” within a 13-cM interval flanked by
markers D11S1765 and D11S4136. Haplotype analysis
also showed that four individuals—III.4, III.12, III.17,
and IV.3, clinically unaffected at the ages of 41, 55, 45,
and 35 years, respectively—have inherited the whole af-
fected haplotype (i.e.,D11S1765–D11S4136). These four
individuals were independently examined on two oc-
casions, but none showed signs of disease. Of these four
individuals, III.4 has passed on the complete affected
haplotype to an affected daughter, age 18 years, but is
herself clinically unaffected at the age of 41 years (fig.
2). Three other unaffected individuals—III.14, IV.2, and
IV.4—have inherited a portion of the affected haplotype
—D11S1765–D11S4095, D11S1765–D11S1889, and
D11S4113–D11S4136, respectively. These data suggest
that the penetrance of SPG17, as determined in family
1, is ∼.66 by the age of 40 years and .92 by the age of
55 years.
Linkage of SS to chromosome 11q12-q14 was also
examined in the affected members of family 2, who
display a similar pattern of amyotrophy of the hand
muscles and a highly variable age at onset, for mark-
ers D11S1883, D11S4113, D114136, D114196,
D11S4139, and D11S916 (fig. 3). In family 2, SS
clearly does not segregate with these markers. Two-
point LOD scores generated by an affecteds-only
model ( ), for markers D11S1883, D11S4113,vp .001
D114136, D114196, D11S4139, and D11S916, were
2.88, 2.53, 2.30, 2.30, 2.30, and 2.04, re-
spectively, which demonstrates further genetic heter-
ogeneity of HSP, even within this rare subtype.
Despite the large number of HSP loci already estab-
lished, many families do not show evidence of linkage
to any of these regions (McDermott et al. 2000). Using
a single large family (i.e., family 1), we have identified,
on chromosome 11q12-q14, a locus containing a gene,
SPG17, that causes SS, a complicated form of HSP. Var-
iable penetrance appears to be a characteristic of SS,
consistent with other studies that suggest a highly var-
iable age at onset of other forms of the disease (Gigli et
al. 1993; Byrne et al. 1998; Fontaine et al. 2000).
Recent studies have begun to determine the molecular
pathogenesis of some forms of this heterogeneous dis-
ease. Mutations of the genes encoding paraplegin and
spastin underlie, respectively, autosomal recessive and
autosomal dominant forms of HSP. These genes encode
AAA proteins (i.e., ATPases associated with diverse cel-
lular activities). Although distantly related, paraplegin
and spastin are thought to have divergent roles, sharing
little homology outside their AAA motifs. Although little
is known about the nuclear molecule spastin, paraplegin
is thought to be a mitochondrial chaperone with ho-
mology to the yeast ATPase AFG3. In yeast, AFG3 is
part of a membrane-bound complex with ATP-depen-
dent protease activity. Similarly, AFG3 exhibits a chap-
erone-like function, mediating assembly of membrane-
associated ATP synthase (Arlt et al. 1996).
The gene for copper chaperone for superoxide dis-
mutase (CCS) has recently been mapped within the SS
locus on chromosome 11q (i.e., SPG17) (Bartnikas et
al. 2000). Although its function is clearly different from
that of paraplegin, CCS donates copper to the homo-
dimeric enzyme SOD1, the principal function of which
is believed to be the detoxification of superoxide radi-
cals. SOD1 is mutated in ∼20% of patients with familial
amyotrophic lateral sclerosis (ALS) (Deng et al. 1993;
Rosen et al. 1993; Casareno et al. 1998). ALS and
HSP—particularly, the SS variant—share a number of
features, including spasticity, muscle weakness and amy-
otrophy, and pathological changes in corticospinal tracts
and in anterior horn cells (Harding 1993). In view of
this, we are currently evaluating patients with SS, for
disease-associated mutations of CCS.
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